患者管理:肥胖男性低睾酮浓度的处理策略
本文阐述肥胖男性血清睾酮轻度至中度降低多属非性腺疾病综合征,表现为睾酮与SHBG成比例降低而LH、FSH正常,即肥胖性假性性腺功能减退。减重及优化2型糖尿病、阻塞性睡眠呼吸暂停、抑郁等合并症管理可逆转睾酮降低;无病理性性腺功能减退时睾酮治疗无指征,超说明书使用可致不育、血细胞比容升高需静脉放血、促血栓状态及睾酮依赖。
要点
- 肥胖男性睾酮与SHBG成比例降低且LH、FSH正常,提示真性腺功能正常,属肥胖性假性性腺功能减退。
- 减重及优化2型糖尿病、阻塞性睡眠呼吸暂停、抑郁等合并症管理可逆转肥胖相关睾酮降低。
- 无病理性性腺功能减退时睾酮治疗无指征,超说明书使用可致不育、血细胞比容升高需静脉放血、促血栓状态及睾酮依赖。
核心结论
- 肥胖不是病理性性腺功能减退的病因;肥胖男性睾酮与SHBG成比例降低伴LH、FSH正常提示真性腺功能正常,即肥胖性假性性腺功能减退。
- 临床显著减重可大幅逆转肥胖相关血清睾酮降低,并改善类似但并非雄激素缺乏所致的非特异性症状。
- 无病理性性腺功能减退时睾酮治疗无指征,且效果不及饮食与生活方式干预;超说明书使用可致不育、血细胞比容升高需静脉放血、促血栓状态及睾酮依赖。
研究设计与样本
- 本文为面向临床医生的患者管理方法综述,未报告系统检索范围与样本量。
主要发现
- 肥胖相关SHBG降低是血清睾酮测定值降低的主要原因,SHBG为睾酮主要循环载体蛋白。
- 肥胖男性睾酮与SHBG成比例降低且LH、FSH正常,确认真性腺功能正常,即肥胖性假性性腺功能减退。
- 临床显著减重可大幅逆转肥胖相关血清睾酮降低,并改善类似但并非雄激素缺乏所致的非特异性症状。
- 无病理性性腺功能减退时,睾酮治疗纠正可逆条件的效果不及饮食与生活方式干预。
关键数值与推荐
- 病理性性腺功能减退指血清睾酮因下丘脑-垂体-睾丸轴不可逆器质性(结构性、遗传性)疾病而显著且持续降低,需终身睾酮替代治疗。
- 肥胖男性睾酮与SHBG成比例降低伴LH、FSH正常,确认真性腺功能正常,即肥胖性假性性腺功能减退。
- 无病理性性腺功能减退时睾酮治疗无指征。
临床怎么用
- 可逆步骤包括减重、优化2型糖尿病、阻塞性睡眠呼吸暂停、抑郁及其他肥胖相关合并症的管理,以及合理化合并用药方案。
- 无病理性性腺功能减退时睾酮治疗无指征,超说明书使用可致不育、血细胞比容升高需静脉放血、促血栓状态及睾酮依赖。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pathologic hypogonadism occurs when serum testosterone is significantly and persistently reduced by irreversible organic (structural, genetic) disorders of the hypothalamic pituitary testicular axis. Men with pathologic hypogonadism require lifelong testosterone replacement. In contrast, mild or moderate reductions in serum testosterone frequently accompany obesity, and its numerous comorbidities in men are best considered nongonadal illness syndromes, wherein reduction in serum testosterone is usually reversible upon amelioration of the underlying nongonadal illness. Obesity can result in nonspecific symptoms in conjunction with reduced serum testosterone and serum SHBG. Obesity-related reductions in SHBG, testosterone's principal circulating carrier protein, are primarily responsible for measured reductions in testosterone. However, obesity is not a cause of pathological hypogonadism, and proportionately reduced testosterone and SHBG concentrations accompanied by normal serum LH and FSH concentrations confirm a eugonadal state, best described as the pseudo-hypogonadism of obesity. Herein we demonstrate how clinically significant weight loss substantially reverses obesity-related reductions in serum testosterone and ameliorates nonspecific symptoms resembling, but not due to, androgen deficiency. The important reversible steps include weight reduction and optimizing management of type 2 diabetes mellitus, obstructive sleep apnea, depression, and other obesity-related comorbidities as well as rationalizing concomitant drug regimens. In the absence of pathological hypogonadism, testosterone treatment is less effective than a diet and lifestyle intervention to rectify the reversible conditions responsible for the nonspecific symptoms and associated reduced serum testosterone concentrations observed in men with obesity. As such, testosterone treatment is not indicated, and unwarranted off-label testosterone treatment can lead to adverse effects such as infertility, elevated hematocrit requiring venesection, a prothrombotic state, and testosterone dependence.
引用
- Muir CA, Wittert GA, Handelsman DJ, et al. Approach to the Patient: Low Testosterone Concentrations in Men With Obesity. J Clin Endocrinol Metab. 2025. PMID: 40052430. doi:10.1210/clinem/dgaf137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。